Payal D. Shah
YOU?
Author Swipe
View article: Long-term Immune Checkpoint Inhibition Therapy for Advanced Stage Merkel Cell Carcinoma
Long-term Immune Checkpoint Inhibition Therapy for Advanced Stage Merkel Cell Carcinoma Open
View article: Penile calciphylaxis: surgical management in the setting of Fournier’s gangrene—a case report and literature review
Penile calciphylaxis: surgical management in the setting of Fournier’s gangrene—a case report and literature review Open
A review of 19 operative case reports on penile calciphylaxis highlights varied management strategies for this highly morbid condition. Current evidence suggests that treatment should be tailored to disease severity. In severe cases with i…
View article: Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy
Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy Open
Over a median of 5.1 years, modest changes in cardiac function were observed with RT. Maximum LAD dose was associated with a worsening in systolic and diastolic function parameters.
View article: Watershed Management Using an Integrated Approach to Preserve and Enhance Water Quality
Watershed Management Using an Integrated Approach to Preserve and Enhance Water Quality Open
View article: Carpal Tunnel Corticosteroid Injection Treatment of Nail Lichen Planus
Carpal Tunnel Corticosteroid Injection Treatment of Nail Lichen Planus Open
Treatment for nail lichen planus (NLP) typically involves the use of intralesional or systemic corticosteroids. However, both modalities have distinct considerations. Systemic options are typically reserved for severe cases due to potentia…
View article: Investigating the Impact of Financial Sponsorship in Dermatology Research
Investigating the Impact of Financial Sponsorship in Dermatology Research Open
Introduction: Financial sponsorship plays a crucial role in advancing dermatologic research, yet its impact on research quality and visibility is not well-defined. This study aims to evaluate the association between financial sponsorship a…
View article: Comparative Study of Red Blood Cell Parameters in Different Hemoglobinopathies Diagnosed by HPLC at a Tertiary Care Hospital, Rajkot, Gujarat
Comparative Study of Red Blood Cell Parameters in Different Hemoglobinopathies Diagnosed by HPLC at a Tertiary Care Hospital, Rajkot, Gujarat Open
Background: Inherited disorders of hemoglobin (hemoglobinopathies) are the most common genetic disorders in the world with 7% prevalence. Thalassemia and sickle cell anemia are the most prevalent hemoglobinopathies in India. Screening and …
View article: Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Representativeness of Study Participants
View article: Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial protocol
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial schema
View article: Data from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Data from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to poly-ADP ribose polymerase inhibitors (PARPi) overcomes PARPi-resistance in high grade serous ovarian cancer (HGSOC) cell and mouse models. We present …
View article: Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial protocol
View article: Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Representativeness of Study Participants
View article: Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Open
Trial schema
View article: Rising Stars in Dermatology: Analysis of Lead Authorship Roles in the Published Literature
Rising Stars in Dermatology: Analysis of Lead Authorship Roles in the Published Literature Open
Introduction: The quality and progression of dermatologic research is significantly impacted by the contribution of first authors at different stages of their careers. Our study examines the association between first-author academic degree…
View article: The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study
The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study Open
RPNs can improve clinical retention for patients with OUD, particularly for individuals experiencing several sociodemographic and clinical factors that are typically correlated with discontinuation of care.
View article: Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Nanostring gene expression data related to Figure 5 and Figure S5 with related metatdata tables.
View article: Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 6. EMT6 tumors do not respond to single-agent chemotherapy. (A) EMT6 parental or B7-H4+ tumors treated with vehicle (isotype control), anti-PD-L1, paclitaxel chemotherapy, or anti-PD-L1 + paclitaxel (n=15/group parental…
View article: FIGURE 6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 expression does not correlate with resistance to chemotherapy + immunotherapy in human breast tumors. Patients were from the I-SPY2 clinical trial (paclitaxel control and pembrolizumab arms) or the TBCRC 043 clinical trial (carboplat…
View article: Table S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplementary Table 2. DE genes between isotype treated and anti-PD-L1 treated EMT6-B7-H4+ tumors.
View article: Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Nanostring gene expression data related to Figure 5 and Figure S5 with related metatdata tables.
View article: FIGURE 2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 (VTCN1) is highly correlated with epithelial gene markers in mouse and human cells unlike other checkpoint ligands. A, In human breast cancer cell lines (CCLE), B7-H4 is the only checkpoint ligand positively correlated …
View article: Table S3 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S3 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplementary Table 3. DE genes between isotype treated EMT6 and EMT6-B7-H4+ tumors, early timepoint, 7 days post isotype treatment.
View article: FIGURE 1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
B7-H4 is associated with immune cold tumors and correlated with worse outcomes. A, Representative TNBC samples (residual disease, post-NAC) categorized on the basis of CD8 T-cell infiltration and localization into ID, MR, SR, and FI…
View article: Figure S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 2. B7-H4 expression is not affected by type I or II interferon or TGF-β treatment in vitro. MMTV-neu epithelial cells that have high levels of endogenous B7-H4 were treated for 72 hours with IFNα or IFNγ at 100ng/mL. B7…
View article: FIGURE 5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
FIGURE 5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Anti-PD-L1 did not induce a proinflammatory immune response in B7-H4+ tumors. CD45+ cells were sorted from EMT6 tumors ± B7-H4 and subjected to NanoString gene expression analysis using the Mouse Pan-Cancer Immune Pan…
View article: Figure S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 4. B7-H4 expression did not change quantity of infiltrating tumor immune cells in vivo regardless of anti-PD-L1 treatment. Untreated and anti-PD-L1 treated EMT6 tumors ± B7-H4 were dissociated to single cell suspension …
View article: Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 6. EMT6 tumors do not respond to single-agent chemotherapy. (A) EMT6 parental or B7-H4+ tumors treated with vehicle (isotype control), anti-PD-L1, paclitaxel chemotherapy, or anti-PD-L1 + paclitaxel (n=15/group parental…
View article: Figure S5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Figure S5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antib…
View article: Table S1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Table S1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer Open
Supplementary Table 1. DE genes between isotype treated and anti-PD-L1 treated EMT6 tumors.